Skip to main content
. Author manuscript; available in PMC: 2014 Nov 24.
Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):315–323. doi: 10.1097/QAI.0b013e3182a21611

Table 2.

Patient Characteristics Stratified by Study Arm

Targeted
N=1,451
Universal
N=1,911
Seroprevalence*
N=1,948
N (%) N (%) N (%)
Age 18–29 559 (38.5) 685 (35.8) 497 (25.5)
30–39 300 (20.7) 384 (20.1) 360 (18.5)
40–49 339 (23.4) 444 (23.2) 447 (22.9)
50–64 256 (17.6) 402 (21.0) 608 (31.2)
Not documented -- -- -- -- 36 (1.8)
Sex^ Male 736 (50.7) 951 (49.8) 955 (49.9)
Female 713 (49.1) 955 (50.0) 963 (49.4)
Not documented 4 (0.3) 9 (0.5) 30 (1.5)
Transgendered 1 (0.1) 0 (0.0) 0 (0.0)
Race White 530 (36.5) 716 (37.5) 820 (42.1)
Black 886 (61.1) 1131 (59.2) 990 (50.8)
Hispanic 23 (1.6) 46 (2.4) 0 (0.0)
Other/Not documented 15 (1.0) 22 (1.2) 138 (7.1)
Last HIV test Never 362 (24.9) 548 (28.7) 199 (10.2)
Last year 364 (25.1) 446 (23.3) 323 (16.6)
Over one year ago 676 (46.6) 868 (45.4) 397 (20.4)
Not documented 52 (3.6) 53 (2.8) 1029 (52.8)
Multiple partners, not always using condoms# 618 (42.6) 647 (33.9) 243 (12.5)
Person ever
having vaginal sex 1,253 (86.4) 1,622 (84.9) 899 (46.1)
having any anal sex 323 (22.3) 351 (18.4) 175 (9.0)
receiving anal sex 167 (11.5) 193 (10.1) 108 (5.5)
giving anal sex 188 (13.0) 187 (9.8) 83 (4.3)
having sex with an at-risk partner 509 (35.1) 544 (28.5) 291 (14.9)
man having sex with men 49 (6.7) 50 (2.6) 20 (2.1)
having sex with a prisoner 377 (26.0) 397 (20.8) 201 (10.3)
having sex with an iv drug user 137 (9.4) 146 (7.6) 72 (3.7)
having sex with a std positive partner 89 (6.1) 90 (4.7) 70 (3.6)
having sex with an HIV positive partner 20 (1.4) 16 (0.8) 2 (0.1)
having sex under the influence 841 (57.8) 953 (49.9) 558 (28.6)
trading drugs or money for sex 146 (10.1) 147 (7.7) 77 (4.0)
had a prior std 741 (51.1) 852 (44.6) 446 (22.9)
used injection drugs 131 (9.0) 134 (7.0) 121 (6.2)
ever used crack& 311 (21.4) 287 (15.0) 329 (16.9)

Missing data was coded as “none reported”. Approximately 8% of risk data (sexual and other risk) for the targeted and universal arms was missing and in the seroprevalence arm approximately 1% of the risk data was missing.

*

Combined seroprevalence estimate (prospective consecutive enrollment + remnant sample collection)

^

Sex as perceived by patient

#

Within the past year

&

defined as non-injected cocaine use in seroprevolence study